
Cell Replacement Therapy Shows Promise in Early Studies—What We Know So Far
Vertex Pharmaceuticals is testing an approach that replaces damaged insulin-producing cells. Early participants have achieved insulin independence, but the therapy is still new and requires careful monitoring.
Key takeaways
- Vertex is developing a cell replacement strategy that infuses synthesized beta cells into the liver via the portal vein
- Early study participants have stopped insulin injections and achieved normal blood sugar levels without them
- The therapy is in early stages and requires low-dose immunosuppression to prevent the body from rejecting the new cells
- This is not a cure yet—it's a promising experimental treatment that may offer an alternative to daily insulin therapy
A Different Approach: Replacing Beta Cells
Type 1 diabetes damages the beta cells in your pancreas that produce insulin. Rather than trying to fix those damaged cells, Vertex Pharmaceuticals is exploring whether synthetic beta cells can do the job instead.
The approach works by infusing these lab-grown beta cells into the portal vein—a blood vessel that carries blood directly to the liver. Once there, the cells establish themselves and begin producing insulin, glucagon, and other hormones naturally produced by a healthy pancreas.
What Early Results Show
In the early participants treated so far, the results have been striking: blood sugar levels are completely normal without insulin injections. The synthesized cells appear to be functioning like natural beta cells, regulating glucose levels on their own.
These early findings represent a meaningful shift in what's possible for some people with Type 1 diabetes, moving the conversation from managing the disease toward potentially replacing the cells it damages.
The Catch: Immunosuppression
Because the new cells are not the person's own cells, the immune system can recognize them as foreign and attack them. To prevent rejection, participants must take low-dose immunosuppressive medications.
This is an important consideration. While insulin independence is significant, the need for ongoing immunosuppression means this therapy carries different risks and trade-offs than insulin alone. More research is needed to understand the long-term safety and effectiveness of this approach.
Still Very Early
Vertex is currently a leader in this field, but cell replacement therapy remains experimental. The number of people treated so far is small, and we don't yet know how long the benefits will last, how well this works across larger populations, or what the long-term effects of immunosuppression might be.
While early results are encouraging, this is not a cure available today. As with any emerging therapy, much more research and testing are needed before we know whether this approach will become a standard treatment option.
Evidence label
Origin: YouTube / Taking Control Of Your Diabetes® (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Cure & AdvancementsHow Beta Cells Respond to Different Threats in Type 1 Diabetes
- Cure & AdvancementsNew Research Directions in Type 1 Diabetes: From Immune Reset to Stem Cell Therapies
- Cure & AdvancementsTeplizumab: The First Disease-Modifying Therapy for Type 1 Diabetes
- Cure & AdvancementsFDA-Approved Teplizumab: What We Know About Delaying Type 1 Diabetes
- Cure & AdvancementsFirst Human Receives Transplant of Lab-Made Insulin-Producing Cells Without Rejection
- Cure & AdvancementsMinimally Invasive Transplant Procedure Shows Early Promise for Type 1 Diabetes Patients in Chicago